TH

E J

OU

RN

AL

OF

PREDICT PREVENT PERSONALIZE WITH PRECISION

P E R S O N A L I Z E

“And it ought to be remembered that there is nothing more difficult to take in hand, more perilous to conduct, or

more uncertain in its success, than to take the lead in the introduction of a new order of things.”

Niccolò Machiavelli, The Prince

M E D I A K I T 2 0 1 5

W elcome to The Journal of Precision Medicine

Note from The Editor

The idea behind The Journal of Precision Medicine has been percolating for some time but the roots of this

concept were borne out of countless discussions we had over the years at various Industry events with numerous

stakeholders from all sides of the Life Science Industry. The rhetoric followed a similar vein, the repetitious,well

worn statements that the Pharma Industry had flatlined, the corporate management culture was sclerotic and

that target selection was based on very little targeted rationale whatsoever. The general consensus was the system

was broken, productivity was down, attrition was high and investor morale was low. Dwindling pipelines and an

ever increasing number of late stage failures suggested a new framework was needed. As a result of what we learnt

from the mapping of the Human Genome, we were beginning to understand more clearly the role of genetics

and the potential that genomic technologies could play in predicting disease. In addition, notwithstanding that

Genomic medicine can offer real hope there are many complex issues surrounding this revolution that need to be

addressed and discussed in an open and collaborative environment.

The Journal of Precision Medicine will do exactly this It will cover a comprehensive timeline from discovery to

diagnosis and discuss the confluence of genomic technologies and diagnostic tools that will play their part in

detecting disease and offer insights into therapeutic solutions for a range of hitherto unmet medical needs. We

will set out to encourage challenging debate surrounding payers, providers and regulators. We’ll discuss the

bioethical and legal ramifications of Big Data and most importantly issues surrounding patient engagement.

We will also look beyond oncology, and discuss how Biomarker R&D efforts could extend into new therapeutics

areas such as Immunology, Infectious Diseases and CNS disorders. We shall also cover the re-alignments Industry

will have to make concerning the adoption and integration of Companion Diagnostics and how to navigate the

regulatory path to ensure commercial success.

With a clearer picture of the many molecular pathways and the heterogeneity of many diseases such as cancer

and diabetes, we are unquestionably at an inflection point in modern medicine. Despite some tremendous

advancements in this field, progress is still too slow, so The Journal of Precision Medicine is committed to

highlighting the obstacles we all face as participants of this endeavour, and through global engagement on

all these issues we will ultimately drive the concept and reality of Precision medicine forward.

Damian Doherty The Editor

P E R S O N A L I Z E

Field Notes 2 short reports on new trends or developments in the Precision Medicine Field

SNPshot A focus on a particular disease area and progress being made in the

advancement of new precision therapies.

2020We talk to a visionary about their career path in science, how it has shaped their current perspective

in this evolving field and ask for some predictions for the future of Precision Medicine.

The Hub A report on a region that is building public/private partnerships and promoting inward

investment to further the advancement of Precison Medicine.

1

2

3

4

We will be producing Bi-Monthly Features

‘The Journal of Precision Medicine will play an important role in advancing the progress already

being made in this exciting field’.

14,500

8,500

2,000

US

A

Europ

e

R o

f WGeographical Breakdown

USA

EUROPE

REST OF THE WORLD

P E R S O N A L I Z E

Industry 52%

Academic 28%

Clinical 1

2%

Gov

ernm

ent

5%O

ther

3%

Institution

Industry 52% Pharma/BioPharm/Biotech/CRO’s

Academic 28% Centers of Excellence, Precision Medicine Institutes, Universities, Research Institutes

Clinical 12% Hospitals, Independent Labs, Core Labs, Reference Labs, CLIA Labs

Government 5% Regulatory Bodies, Institutions

Other 3% Healthcare Providers/ Healthcare Agencies/ Patient Advocate Groups

INDUSTRY

AC ADEMIC

CL IN IC AL

GOVERNMENT

OTHER

P E R S O N A L I Z E

Job Profile

Research

Scientists

Clinical Scientists

BiomarkerR&D

Drug Discovery

Heads ofPathology

Heads of Research

Genetics

Directors of Precision Medicine

Drug SafetyHeads of

Translational Medicine

Heads of Clinical

R&D

Heads of Dx

Directors of Clinical

Trials

Computational

Heads of Experimental

Medicine

Proteomics

Genomics

Metabolomics

EpigenomicsMicrobiomics

We’ll produce a monthly E-Newsletter which will incorporate a roundup of news/features and video covering a range of topics

such as (but are not limited to)

P E R S O N A L I Z E

GenomicsEpigeneticsMol Dx Proteomics

Transcriptomics

Companion Dx

Biomarkers

Genetic TestingGene Therapy

Clinical InformaticsDigital HealthSynthetic Biology

Clinical Chemistry

3D Bioprinting

Reimbursement

NEXT GENERATION SEQUENCING

Artificial IntelligenceRegenerative

MedicineLegal, bioethical and social implications of Precision medicine

Big Data

Drug safety/dosage

Gene based clinical trials

Digital Media

The Journal of Precision Medicine will create an active environment on Linkedin and Twitter.

Delivering our Snpits to an audience eager to learn more about this dynamic space, encouraging

followers to engage in reading, sharing and participating in a continuous flow of dialogue, we

aim to be an invaluable resource and platform to further discussion on the critical issues facing

Pharma, Biotech and Diagnostic companies in the Personalised Medicine landscape.

The Website will be launched in Jan 2015 offering news features and investigative snapshots of

developments in the field of Precision Medicine. We’ll also be producing an interactive app version on

multiple platforms – beginning with the Apple Newsstand and Google Play.

The app will allow for rich media content to be woven seamlessly into the long word format,

use of interactive infographics with dynamic explainer videos will maximise impact and

engagement factor. We will also be producing bespoke online supplements focusing on various

therapeutic areas and highlighting new technology offerings and their application. With

exponential growth in the use of tablets and hand held devices we see huge opportunities in

extending the reach of the journal to new readers around the globe.

P E R S O N A L I Z E P E R S O N A L I Z E

Event Schedule

These are some of the conferences we will be attending or exhibiting at in 2015.

PMWC 26-28 January 2015 Mountain View, California

Molecular Med Tri Con 15-20 February 2015 San Francisco

PMWC 2015 UK 15-17 April 2015 Oxford UK

AACR 18-22 April 2015 Philadelphia

Biomarkers & Diagnostics World Conference 5-7 May 2015 Philadelphia

ASCO 29 May - 2 June 2 2015 Chicago

ISSCR 24-27 June 2015 Stockholm

AACC 26-30 July 2015 Atlanta

Precision Medicine Congress 14-15 September 2015 London

ASHG 6-10 October 2015 Baltimore

ASCB 12-16 December 2015 San Diego